Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Amphastar Pharmaceuticals (AMPH) EPS (Basic) (2016 - 2025)

Amphastar Pharmaceuticals (AMPH) has 13 years of EPS (Basic) data on record, last reported at $0.53 in Q4 2025.

  • For Q4 2025, EPS (Basic) fell 32.91% year-over-year to $0.53; the TTM value through Dec 2025 reached $2.1, down 36.17%, while the annual FY2025 figure was $2.1, 36.17% down from the prior year.
  • EPS (Basic) reached $0.53 in Q4 2025 per AMPH's latest filing, up from $0.38 in the prior quarter.
  • Across five years, EPS (Basic) topped out at $1.02 in Q3 2023 and bottomed at $0.11 in Q1 2021.
  • Average EPS (Basic) over 5 years is $0.57, with a median of $0.54 recorded in 2023.
  • Peak YoY movement for EPS (Basic): surged 1700.0% in 2021, then plummeted 54.22% in 2025.
  • A 5-year view of EPS (Basic) shows it stood at $0.41 in 2021, then soared by 73.17% to $0.71 in 2022, then grew by 5.63% to $0.75 in 2023, then increased by 5.33% to $0.79 in 2024, then crashed by 32.91% to $0.53 in 2025.
  • Per Business Quant database, its latest 3 readings for EPS (Basic) were $0.53 in Q4 2025, $0.38 in Q3 2025, and $0.66 in Q2 2025.